Literature DB >> 6110915

Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens.

J C Stevenson, G Abeyasekera, C J Hillyard, K G Phang, I MacIntyre, S Campbell, P T Townsend, O Young, M I Whitehead.   

Abstract

In man, the major function of calcitonin appears to be prevention of excessive or unwanted bone resorption. There is a striking sex difference in circulating levels, with a relative deficiency in women. Calcitonin secretion in young adults is increased by oestrogens and therefore long periods of oestrogen lack, such as after the menopause, may be associated with a more pronounced calcitonin deficiency. This exaggerated deficiency could be an important factor in the pathogenesis of postmenopausal bone loss, especially since the latter may be due to excessive bone resorption. In a study of the effects of oestrogen treatment on circulating levels of calcitonin, parathyroid hormone, and vitamin-D metabolites in postmenopausal women, the most striking change was a sharp rise in plasma-calcitonin. Oestrogens prevent postmenopausal bone loss, and it is suggested that this effect could be mediated, at least in part, through control of calcitonin secretion. Calcitonin may prove effective in the prevention of postmenopausal bone loss, and it is suggested that this effect could be mediated, at least in part, through control of calcitonin secretion. Calcitonin may prove effective in the prevention of postmenopausal bone loss. Its place in the treatment of postmenopausal osteoporosis warrants further evaluation.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents, Estrogen--therapeutic use; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents--therapeutic use; Endocrine System; Estradiol--therapeutic use; Estrogens; Ethinyl Estradiol--therapeutic use; Family Planning; Gonadotropins; Hemic System; Hormones; Menopause; Physiology; Reproduction; Serum Calcium Level--analysis

Mesh:

Substances:

Year:  1981        PMID: 6110915     DOI: 10.1016/s0140-6736(81)91973-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  35 in total

1.  Calcitonin and estrogens.

Authors:  D Agnusdei; R Civitelli; A Camporeale; C Gennari
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

2.  The effects of menopause and estrogen replacement therapy on the renal handling of calcium.

Authors:  S Adami; D Gatti; F Bertoldo; M Rossini; A Fratta-Pasini; N Zamberlan; E Facci; V Lo Cascio
Journal:  Osteoporos Int       Date:  1992-07       Impact factor: 4.507

3.  Serum bone Gla protein in streak gonad syndrome.

Authors:  J Zséli; P Bösze; P Lakatos; P Vargha; G Tarján; E Kollin; C Horváth; J László; I Holló
Journal:  Calcif Tissue Int       Date:  1991-06       Impact factor: 4.333

Review 4.  Role of oestrogen in the development of osteoporosis.

Authors:  T C Hillard; J C Stevenson
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

5.  Osteoporosis: Part II. Prevention of Bone Loss and Fractures in Women and Risks of Menopausal Estrogen Therapy.

Authors: 
Journal:  West J Med       Date:  1983-08

Review 6.  Peptides from the calcitonin genes: molecular genetics, structure and function.

Authors:  L H Breimer; I MacIntyre; M Zaidi
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

7.  Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.

Authors:  M Cortellaro; T Nencioni; C Boschetti; S Ortolani; F Buzzi; B Francucci; M P Caraceni; P Abelli; F Polvani; C Zanussi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women.

Authors:  M Meschia; M Brincat; P Barbacini; P G Crossignani; W Albisetti
Journal:  Calcif Tissue Int       Date:  1993-07       Impact factor: 4.333

9.  Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line.

Authors:  A H Gorn; H Y Lin; M Yamin; P E Auron; M R Flannery; D R Tapp; C A Manning; H F Lodish; S M Krane; S R Goldring
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Biochemical short-term changes produced by hormonal replacement therapy.

Authors:  J F Aloia; A Vaswani; J K Yeh; D M McGowan; P Ross
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.